Common scenarios and what to do Theory is helpful, but real life creates situations that do not fit neatly into storage guidelines

Suitable candidates include: Patients with type 2 diabetes and a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or other minority ethnic backgrounds), or where weight loss would benefit other significant obesity-related comorbidities Those with type 2 diabetes who have not achieved target HbA1c levels with metformin and other oral medications People for whom weight loss would benefit other obesity-related comorbidities or where weight-neutral treatment options are preferred Individuals with occupational implications where insulin therapy would be problematic Importantly, NICE recommends continuing GLP-1 receptor agonist treatment only if there is a beneficial metabolic response: after 6 months, treatment should continue only if HbA1c has decreased by at least 11 mmol/mol (1.0%) and weight has decreased by at least 3% from initial body weight

Our mission is simple - we aim to increase the accessibility and affordability of life changing GLP-1 products like Semaglutide and Tirzepatide
We prefer cycles rather than indefinite use
The clinical evidence supporting tirzepatide and metformin combination therapy comes primarily from large-scale randomized controlled trials, though most were designed to evaluate tirzepatide's efficacy rather than specifically examine synergistic effects with metformin
The telehealth partner is responsible for clinical assessment, prescriptions, and pharmacy fulfillment